Z. Mršić-Krmpotić

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.

M. Inbar, C. Wiltschke, T. Brodowicz, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer

J. Jassem, V. Gorbunova, S. Jelić, 1999 .

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

T. Ciuleanu, D. Radosavljevic, T. Brodowicz, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

W. Scheithauer, T. Ciuleanu, F. Wrba, 2010, World journal of gastroenterology.

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

J. Jassem, A. Płużańska, T. Pieńkowski, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

J. Forbes, M. Buyse, G. Sauter, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

T. Ciuleanu, T. Brodowicz, M. Dank, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.